Delivered with gamma-ray irradiation incorporated into a single-use system. Ideal for the single-use process of antibody manufacturing and virus removal!
The "Pegasus(TM) Prime Virus Filter" reliably removes viruses, protecting critical biopharmaceutical manufacturing processes from viral contamination and ensuring the quality of pharmaceuticals and safety for health. Delivered gamma-irradiated from small scale to process scale, it features high flow rates and stable filtration performance, enabling process simplification, reduction, and continuous cost savings across a wide range of scales. [Features] - Stable high virus removal performance regardless of process fluids or parameters - Stable filtration performance with high flow rates - Gamma sterilized - Scalable - Constant filtration area ratio of pre-filters to virus filters across all scales For more details, please refer to the catalog or feel free to contact us.
Inquire About This Product
basic information
Virus filters that enable the single-use of virus filtration processes ■ Can be integrated into single-use systems and subjected to gamma irradiation collectively ◎ Achieves single-use of the virus removal process ◎ Dedicated pre-filters for aggregate removal can also be integrated and subjected to gamma irradiation ■ Configurable within a wide process design space ◎ Maximizes process flexibility and minimizes deviation risk ■ Space-saving and short filtration process time ◎ Enables continuous cost reduction ◎ Easy to implement in automated processes ■ Filtration performance applicable at all scales ◎ Simple process development ■ Controls the risk of scale changes ◎ Quick and straightforward scale-up ■ Excellent operability ◎ Integrity testing can be performed using the same operation as filtration sterilization filters *For more details, please refer to the catalog or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Purpose】 Manufacturing of antibody drugs - Virus removal process Research and development *For more details, please refer to the catalog or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
